Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.

Freedland, S J; Hamilton, R J; Gerber, L; Banez, L L; Moreira, D M; Andriole, G L; Rittmaster, R S

Freedland, S J; Hamilton, R J; Gerber, L; Banez, L L; Moreira, D M; Andriole, G L; Rittmaster, R S.

Affiliation

Freedland SJ; Surgery Section, Durham VA Medical Center, Durham, NC, USA. Steve.freedland@duke.edu

Prostate Cancer Prostatic Dis ; 16(3): 254-9, 2013 Sep.

Article in En | MEDLINE | ID: mdl-23567655

Subject(s)

Azasteroids/therapeutic use; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage; Prostatic Neoplasms/drug therapy; Prostatic Neoplasms/epidemiology; Biopsy; Double-Blind Method; Dutasteride; Early Detection of Cancer/methods; Humans; Kallikreins/blood; Logistic Models; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen/blood; Prostatic Neoplasms/blood; Prostatic Neoplasms/pathology; Risk; United States/epidemiology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Azasteroids / Hydroxymethylglutaryl-CoA Reductase Inhibitors Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limits: Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Prostate Cancer Prostatic Dis Journal subject: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Year: 2013 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google